One of the more productive partnerships in Wisconsin business ended last week when Baird Venture Partners officially exited its investment in NimbleGen Systems through the sale of NimbleGen to Roche. As a result of the Roche acquisition, NimbleGen will return a meaningful percentage of capital...
Jeff Williams, the new chief executive of Platypus Technologies, was brought back to Madison for his expertise in commercializing technology, and his new company will be giving him plenty of practice at bringing products to market. Platypus, which has developed nanotechnology-based research tools, is ready...
Tech transfer has several faces, including the medical informatics so prevalent in the Wisconsin economy, and two University of Wisconsin-Madison professors have developed software to add to that profile. Ray Vanderby and Hiro Kobayashi are pursuing a WARF patent for technology that images and quantifies...
Lucigen, a Madison company that develops gene cloning and protein expression technologies, has received a $250,000 grant from the National Institute of Mental Health. The grant will be used to fund the development of new methods of analyzing membrane proteins that could speed the development...
In a recently completed study, University of Wisconsin-Madison researchers played an integral role in providing new insights into amyotrophic lateral sclerosis or Lou Gehrig's Disease. Their study demonstrates the promise of cell-based therapies for diseases, including ALS, that have been difficult to manage for modern...
In his continuing series on early-stage companies, columnist Joe Boucher has covered many of the financing means for new businesses. For many ventures, both new and established ones, real estate is the most expensive asset to finance, but in this edition of Early Stage, Boucher...
The technology transfer business offers more freedom for a chief information officer, but for Patty Prime, CIO of the Wisconsin Alumni Research Foundation, it also has fast tracked the need to be on top of new e-discovery rules. With an approach that's part process and...
In a trend that bodes well for the Midwest, the region reported a record $742 million in life science venture capital funding in 64 companies during the first half of 2007, good for an average of $11.6 million per funded company, according to Yer Biotech...
For several years, researchers have been working to develop a wide range of potential medical applications for RNA interference, which acts as a genetic "silencing switch." Until a new delivery platform was developed by Mirus Bio Corp., a Madison biotechnology company, there has been no...
A 24 percent increase in clinical molecular diagnostic revenue did not prevent Third Wave Technologies from reporting a net loss of $7.2 million, or $0.17 a share, for the second quarter of 2007. The company, which is on track to report more than $30 million...